JP2021502105A - タンパク質操作された細胞外小胞 - Google Patents

タンパク質操作された細胞外小胞 Download PDF

Info

Publication number
JP2021502105A
JP2021502105A JP2020526180A JP2020526180A JP2021502105A JP 2021502105 A JP2021502105 A JP 2021502105A JP 2020526180 A JP2020526180 A JP 2020526180A JP 2020526180 A JP2020526180 A JP 2020526180A JP 2021502105 A JP2021502105 A JP 2021502105A
Authority
JP
Japan
Prior art keywords
protein
lysosomal
polypeptide
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020526180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021502105A5 (https=
Inventor
ジャスティン・ヒーン
ペル・ルンディン
アンドレ・グルゲンス
Original Assignee
エヴォックス・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヴォックス・セラピューティクス・リミテッド filed Critical エヴォックス・セラピューティクス・リミテッド
Publication of JP2021502105A publication Critical patent/JP2021502105A/ja
Publication of JP2021502105A5 publication Critical patent/JP2021502105A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2020526180A 2017-11-13 2018-11-13 タンパク質操作された細胞外小胞 Pending JP2021502105A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1718681.8 2017-11-13
GBGB1718681.8A GB201718681D0 (en) 2017-11-13 2017-11-13 Protein engineered extracellular vesicles
PCT/EP2018/081122 WO2019092287A1 (en) 2017-11-13 2018-11-13 Protein engineered extracellular vesicles

Publications (2)

Publication Number Publication Date
JP2021502105A true JP2021502105A (ja) 2021-01-28
JP2021502105A5 JP2021502105A5 (https=) 2021-12-23

Family

ID=60788311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526180A Pending JP2021502105A (ja) 2017-11-13 2018-11-13 タンパク質操作された細胞外小胞

Country Status (14)

Country Link
US (1) US20200399591A1 (https=)
EP (1) EP3710022A1 (https=)
JP (1) JP2021502105A (https=)
KR (1) KR20200081487A (https=)
CN (1) CN111601607A (https=)
AU (1) AU2018363212A1 (https=)
BR (1) BR112020007327A2 (https=)
CA (1) CA3082299A1 (https=)
GB (1) GB201718681D0 (https=)
IL (1) IL274124A (https=)
MX (1) MX2020004712A (https=)
RU (1) RU2020119155A (https=)
SG (1) SG11202004200PA (https=)
WO (1) WO2019092287A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023190271A1 (https=) * 2022-03-28 2023-10-05

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152298A1 (en) * 2019-01-24 2020-07-30 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Method for producing enzymes
EP3986429A4 (en) * 2019-06-21 2023-07-19 Entelexo Biotherapeutics Inc. PLATFORMS, COMPOSITIONS, AND METHODS OF ADMINISTRATION OF THERAPEUTICS
CN114616344B (zh) * 2019-10-28 2026-03-31 普赛尔根技术股份公司 用于绘制滚环扩增产物图谱的方法
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
US20210324339A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Ｄｎａ分子の組成物、その作製方法、及びその使用方法
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023193665A1 (zh) * 2022-04-07 2023-10-12 威海纽兰生物科技有限公司 基于细胞外囊泡酯酶响应药物递送载体及其制备方法和用途
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2024107831A1 (en) * 2022-11-15 2024-05-23 Board Of Trustees Of Michigan State University Use of extracellular vesicles as a molecular screening platform
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179227A1 (en) * 2014-05-18 2015-11-26 Children's Medical Center Corporation Methods and compositions relating to exosomes
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
WO2016057755A1 (en) * 2014-10-09 2016-04-14 Anthrogenesis Corporation Placenta-derived adherent cell exosomes and uses thereof
WO2016197196A1 (en) * 2015-06-12 2016-12-15 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179227A1 (en) * 2014-05-18 2015-11-26 Children's Medical Center Corporation Methods and compositions relating to exosomes
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
WO2016057755A1 (en) * 2014-10-09 2016-04-14 Anthrogenesis Corporation Placenta-derived adherent cell exosomes and uses thereof
WO2016197196A1 (en) * 2015-06-12 2016-12-15 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IGLESIAS, D. M. ET AL.: "Stem cell microvesicles transfer cystinosin to human cystinotic cells and reduce cystine accumulatio", PLOS ONE, vol. ７（８）, JPN7022004897, 2012, pages 42840, ISSN: 0005117598 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023190271A1 (https=) * 2022-03-28 2023-10-05
JP7773257B2 (ja) 2022-03-28 2025-11-19 合同会社HiRoko Science ｍｉＲ－１４０を含む医薬組成物及びその製造方法

Also Published As

Publication number Publication date
BR112020007327A2 (pt) 2020-10-06
SG11202004200PA (en) 2020-06-29
IL274124A (en) 2020-06-30
RU2020119155A (ru) 2021-12-15
GB201718681D0 (en) 2017-12-27
CN111601607A (zh) 2020-08-28
RU2020119155A3 (https=) 2022-03-21
KR20200081487A (ko) 2020-07-07
WO2019092287A1 (en) 2019-05-16
EP3710022A1 (en) 2020-09-23
AU2018363212A1 (en) 2020-05-28
MX2020004712A (es) 2020-11-06
US20200399591A1 (en) 2020-12-24
CA3082299A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
JP2021502105A (ja) タンパク質操作された細胞外小胞
JP7483648B2 (ja) 治療的ポリペプチドを含むエクソソーム
JP7077404B2 (ja) Ｒｎａ治療薬を含むエクソソーム
JP7365902B2 (ja) 治療用タンパク質を有するｅｖの負荷の改善
JP2020023503A (ja) バイオ医薬の送達のためのエキソソーム
SG187171A1 (en) Nucleophilic catalysts for oxime linkage
US20250032550A1 (en) A novel way for brain-specific delivery of molecules for the treatment of brain diseases
CN113272426A (zh) 用于尿素循环蛋白和核酸的替代的细胞外囊泡
US20260034239A1 (en) Loaded extracellular vesicle
CA3104432A1 (en) Combinatorial gene therapy
US20240197908A1 (en) Modified extracellular vesicles (evs) with improved half-life
CN115279400A (zh) 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
KR20230034334A (ko) 개선된 반감기를 갖는 세포외 소포
JP2021522791A (ja) Ａａｖ適合性ラミニン−リンカー重合タンパク質
CN120603951A (zh) 用于代谢病症的基因治疗
Graham et al. Receptor-guided AAV Tropism Engineering via MATCH
WO2022266139A2 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240311